drugset / Trial / NCT04090957

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort II)

NCT04090957

Phase 3 Completed 1015 enrolled Estetra ICON Clinical Research · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A two-part study designed to evaluate the effect of Estetrol (E4) 15 mg, 20 mg, or placebo on the severity and frequency of vasomotor symptoms (VMS) in the Efficacy Study Part and the safety of E4 20 mg in the Safety Study Part.

Timeline

Start
2019-09-27
Primary completion
2022-08-18
Completion
2022-08-18

Drugs

EvaluationDrugModalityDoseRoute
Subject ESTETROL ANHYDROUS Other / unclassified 15 mg Oral
Subject ESTETROL ANHYDROUS Other / unclassified 20 mg Oral

Indications

No indication recorded.